There’s a new kid on the block and he can bang up cancer cells very effectively, but, he doesn’t like to discriminate and won’t think a bit about roughing up the kidney as well. This kid has a fancy name – immune checkpoint inhibitor. Oncologists are raving about it, but nephrologists are freaking out about it. How do we solve this mess? Can cancer patients keep receiving these medications even if they have renal adverse events? And what about transplant patients? If you’ve wondered about this yourself, then you’re in luck because we’ll be asking these and similar relevant questions to Dr Sandra Herrmann, a well-known expert in the field of onco-nephrology.